Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
USA is still the largest consumption region of Tekturna, occupied about 56% market share globally, with revenue 39.21 million USD in 2017. At the same time, Asia will see the considerable growth since Noden Pharma DAC had successfully entered into an agreement with Orphan Pacific (Japan) and Lee's Pharmaceutical Holdings Limited (China).
According to this study, over the next five years the Renin-Inhibitors market will register a 5.6% CAGR in terms of revenue, the global market size will reach USD 100 million by 2024, from USD 69 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Renin-Inhibitors business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Renin-Inhibitors market by product type, application, key manufacturers and key regions and countries.
This study considers the Renin-Inhibitors value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
150mg/Tablet
300mg/Tablet
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Age below 45
Age 45-55
Age 55-65
Age above 65
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Novartis
Noden Pharma
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Renin-Inhibitors consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Renin-Inhibitors market by identifying its various subsegments.
Focuses on the key global Renin-Inhibitors manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Renin-Inhibitors with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Renin-Inhibitors submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
